UNSPSC 51122402: Mannitol hexanitrate/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.

UNSPSC 51122402 Mannitol hexanitrate/phenobarbital is a Commodity code that in recent state and local procurement activity represents a narrow slice of emergency medical and pharmaceutical procurement — specifically advanced life support medications and generic pharmaceuticals supplied to fire departments, health agencies, and cooperative purchasing networks. State and local governments buying under this code include city fire departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves supplying individual medication line items with strict expiration-date and shelf-life requirements, compliance with cGMP and DSCSA standards, Safety Data Sheets compliant with OSHA Hazard Communication Standards, and delivery within tight timeframes. Contracts typically run one to three years with renewal or extension options, and issuing bodies reserve the right to award in whole or in part and cancel with notice.

Activity appears concentrated in Texas and Florida, with multistate cooperative purchasing extending into Minnesota and Oregon. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue, requesting four specific medication line items with a $40,000 estimated contract value and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, requiring NDC-specific submissions through authorized wholesalers and weighted evaluation on price competitiveness (75 percent) and compliance with administrative and data-interchange requirements. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013, April 3, 2026) on direct-to-manufacturer prescription programs, indicating early-stage state interest in restructured pharmacy procurement models outside traditional PBM and wholesaler arrangements.